Variability of on-treatment platelet reactivity in patients on clopidogrel

Platelets

Volumn 25, Issue 5, 2014, Pages 328-336

  Freynhofer, Matthias K ^a,b   Bruno, Veronika ^a   Brozovic, Ivan ^a   Jarai, Rudolf ^a   Vogel, Birgit ^a   Farhan, Serdar ^a   Hübl, Wolfgang ^a   Willheim, Martin ^a   Wojta, Johann ^b,c   Huber, Kurt ^a,b  

^a WILHELMINEN HOSPITAL   (Austria)

^b Ludwig Boltzmann Cluster for Cardiovascular Research   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Acute coronary syndromes; Clopidogrel; Coronary artery disease; On treatment platelet reactivity; Vasodilator stimulated phosphoprotein phosphorylation assay

Indexed keywords

ACETYLSALICYLIC ACID; CHOLESTEROL; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; GLUCOSE; HIGH DENSITY LIPOPROTEIN; SIMVASTATIN; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ADULT; ARTICLE; ASSAY; BLOOD SAMPLING; BODY MASS; CLINICAL ASSESSMENT TOOL; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PHENOTYPE; PLATELET REACTIVITY; PLATELET REACTIVITY INDEX; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STEADY STATE; THROMBOCYTE; THROMBOCYTE FUNCTION; TREATMENT OUTCOME; VASODILATOR STIMULATED PHOSPHOPROTEINPHOSPHORYLATION ASSAY; ANALOGS AND DERIVATIVES; BLOOD CLOTTING PARAMETERS; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PROCEDURES; THROMBOCYTE ACTIVATION;

BLOOD PLATELETS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TICLOPIDINE;

EID: 84904002295     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2013.827781     Document Type: Article

References (55)

1. Jaremo P, Lindahl TL, Fransson SG, Richter A. Individual variations of platelet inhibition after loading doses of clopidogrel. J Intern Med 2002;252: 233-238.
2. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003;107: 2908-2913. (Pubitemid 36736631)
3. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The PCI-CURE study. Lancet 2001;358: 527-533. (Pubitemid 32772726)
4. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345: 494-502. (Pubitemid 32758501)
5. Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS. Addition of clopidogrel to aspirin in 45, 852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 2005;366: 1607-1621.
6. Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5: 1630-1636. (Pubitemid 47091403)
7. Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, Buonamici P, Antoniucci D, Abbate R, Gensini GF. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: A 12- month follow-up. Circulation 2009;119: 237-242.
8. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. Jama 2010;303: 754-762.
9. Bonello L, Tantry US, Marcucci R, Blindt R, Angiolillo DJ, Becker R, Bhatt DL, Cattaneo M, Collet JP, Cuisset T, et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol 2010;56: 919-933.
10. Bonello L, Camoin-Jau L, Armero S, Com O, Arques S, Burignat- Bonello C, Giacomoni MP, Bonello R, Collet F, Rossi P, et al. Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis. Am J Cardiol 2009;103: 5-10.
11. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilatorstimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008;51: 1404-1411. (Pubitemid 351447314)
12. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Muller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: Results of the TRIGGERPCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 2012;59: 2159-2164.
13. Collet JP, Cuisset T, Range G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrie D, Boueri Z, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 2012; 367: 2100-2109.
14. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. Jama 2011;305: 1097-1105.
15. Freynhofer MK, Bruno V, Wojta J, Huber K. The role of platelets in athero-thrombotic events. Curr Pharm Des 2012;18: 5197-5214.
16. Wurtz M, Grove EL. Interindividual variability in the efficacy of oral antiplatelet drugs: Definitions, mechanisms and clinical importance. Curr Pharm Des 2012;18: 5344-5361.
17. Madsen EH, Saw J, Kristensen SR, Schmidt EB, Pittendreigh C, Maurer-Spurej E. Long-term aspirin and clopidogrel response evaluated by light transmission aggregometry, Verify Now, and thrombelastography in patients undergoing percutaneous coronary intervention. Clin Chem 2010;56: 839-847.
18. Saw J, Madsen EH, Chan S, Maurer-Spurej E. The ELAPSE (Evaluation of Long-Term Clopidogrel Antiplatelet and Systemic Anti-Inflammatory Effects) study. J Am Coll Cardiol 2008;52: 1826-1833.
19. Jaitner J, Stegherr J, Morath T, Braun S, Bernlochner I, Schomig A, Kastrati A, Sibbing D. Stability of the high on-treatment platelet reactivity phenotype over time in clopidogrel-treated patients. Thromb Haemost 2011;105: 107-112.
20. Leoncini M, Toso A, Maioli M, Angiolillo DJ, Giusti B, Marcucci R, Abbate R, Bellandi F. High-Dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) Study. JACC Cardiovasc Interv 2013;6: 169-179.
21. Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay JF, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial. Am Heart J 2009;157:818-824, 24 e1.
22. King 3rd SB, Smith Jr SC, Hirshfeld Jr JW, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O'Neill WW, Schaff HV, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation 2008;117: 261-295.
23. Wijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, Garg S, Huber K, James S, Knuuti J, et al. Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010;31: 2501-2555.
24. Freynhofer MK, Bruno V, Willheim M, Hubl W, Wojta J, Huber K. Vasodilator-stimulated phosphoprotein-phosphorylation assay in patients on clopidogrel: Does standardisation matter? Thromb Haemost 2012;107: 538-544.
25. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, Marchesini J, Bernardi F, Ferrari R, Valgimigli M. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
26. Gurbel PA, Cummings CC, Bell CR, Alford AB, Meister AF, Serebruany VL. Onset and extent of platelet inhibition by clopidogrel loading in patients undergoing elective coronary stenting: The Plavix Reduction Of New Thrombus Occurrence (PRONTO) trial. Am Heart J 2003;145: 239-247. (Pubitemid 36207944)
27. Gawaz M, Neumann FJ, Ott I, May A, Schomig A. Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996;94: 279-285. (Pubitemid 26266110)
28. Palmerini T, Barozzi C, Tomasi L, Sangiorgi D, Marzocchi A, De Servi S, Ortolani P, Reggiani LB, Alessi L, Lauria G, et al. A randomised study comparing the antiplatelet and antiinflammatory effect of clopidogrel 150 mg/day versus 75 mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study. Thromb Res 2010;125: 309-314.
29. Althoff TF, Fischer M, Langer E, Ziemer S, Baumann G. Sustained enhancement of residual platelet reactivity after coronary stenting in patients with myocardial infarction compared to elective patients. Thromb Res 2010;125:e190-e196.
30. Funck-Jensen KL, Dalsgaard J, Grove EL, Hvas AM, Kristensen SD. Increased platelet aggregation and turnover in the acute phase of STelevation myocardial infarction. Platelets 2012; Dec 5 [epub ahead of print].
31. Guthikonda S, Alviar CL, Vaduganathan M, Arikan M, Tellez A, De Lao T, Granada JF, Dong JF, Kleiman NS, Lev EI. Role of reticulated platelets and platelet size heterogeneity on platelet activity after dual antiplatelet therapy with aspirin and clopidogrel in patients with stable coronary artery disease. J Am Coll Cardiol 2008; 52: 743-749.
32. Freynhofer MK, Bruno V, Brozovic I, Grove EL, Kristensen SD, Willheim M, Hubl W, Huber K. Is increased platelet turnover responsible for low responsiveness to different thienopyridienes? A case report of recurrent stent thromboses. Thromb Haemost 2011; 106: 182-184.
33. Wurtz M, Grove EL, Wulff LN, Kaltoft AK, Tilsted HH, Jensen LO, Hvas AM, Kristensen SD. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. JACC Cardiovasc Interv 2010;3: 828-835.
34. Mach F, Senouf D, Fontana P, Boehlen F, Reber G, Daali Y, de Moerloose P, Sigwart U. Not all statins interfere with clopidogrel during antiplatelet therapy. Eur J Clin Invest 2005;35: 476-481. (Pubitemid 41153201)
35. Jakubowski JA, Payne CD, Li YG, Farid NA, Brandt JT, Small DS, Salazar DE, Winters KJ. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008;99: 215-222.
36. Bliden KP, Dichiara J, Lawal L, Singla A, Antonino MJ, Baker BA, Bailey WL, Tantry US, Gurbel PA. The association of cigarette smoking with enhanced platelet inhibition by clopidogrel. J Am Coll Cardiol 2008;52: 531-533.
37. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, et al. Platelet Function During Extended Prasugrel and Clopidogrel Therapy for Patients With ACS Treated Without Revascularization: The TRILOGY ACS Platelet Function Substudy. JAMA 2012;308: 1785-94. doi: 10.1001/jama.2012.17312.
38. Siller-Matula JM, Lang I, Christ G, Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008;52: 1557-1563.
39. Sarafoff N, Neumann L, Morath T, Bernlochner I, Mehilli J, Schomig A, Kastrati A, Sibbing D. Lack of impact of calciumchannel blockers on the pharmacodynamic effect and the clinical efficacy of clopidogrel after drug-eluting stenting. Am Heart J 2011; 161: 605-610.
40. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Barrera Ramirez C, Sabate M, Fernandez C, Hernandez-Antolin R, Escaned J, Alfonso F, Macaya C. Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loadingdose be weight adjusted? J Invasive Cardiol 2004;16: 169-174. (Pubitemid 38456448)
41. Buonamici P, Marcucci R, Migliorini A, Gensini GF, Santini A, Paniccia R, Moschi G, Gori AM, Abbate R, Antoniucci D. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007;49: 2312-2317. (Pubitemid 46891710)
42. Bonello-Palot N, Armero S, Paganelli F, Mancini J, De Labriolle A, Bonello C, Levy N, Maillard L, Barragan P, Dignat-George F, et al. Relation of body mass index to high on-treatment platelet reactivity and of failed clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;104: 1511-1515.
43. Schafer A, Weinberger S, Flierl U, Eigenthaler M, Stork S, Walter U, Ertl G, Bauersachs J. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 2008;100: 618-625.
44. Schafer A, Flierl U, Kossler J, Seydelmann N, Kobsar A, Stork S, Bauersachs J. Early determination of clopidogrel responsiveness by platelet reactivity indexidentifies patients at risk for cardiovascular events after myocardial infarction. Thromb Haemost 2011;106: 141-148.
45. Davi G, Ganci A, Averna M, Giammarresi C, Barbagallo C, Catalano I, Cala A, Notarbartolo A. Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. Thromb Haemost 1995;74: 1015-1019.
46. Carvalho AC, Colman RW, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974;290: 434-438.
47. Chen LY, Mehta JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sci 1994;55: 1815-1821.
48. Zafar MU, Paz-Yepes M, Shimbo D, Vilahur G, Burg MM, Chaplin W, Fuster V, Davidson KW, Badimon JJ. Anxiety is a better predictor of platelet reactivity in coronary artery disease patients than depression. Eur Heart J 2010;31: 1573-1582.
49. Reny JL, Berdague P, Poncet A, Barazer I, Nolli S, Fabbro-Peray P, Schved JF, Bounameaux H, Mach F, de Moerloose P, et al. Antiplatelet drug response status does not predict recurrent ischemic events in stable cardiovascular patients: Results of the Antiplatelet Drug Resistances and Ischemic Events study. Circulation 2012;125: 3201-3210.
50. van Werkum JW, Ten Berg JM. Platelet reactivity over time: Solid as a rock or not durable? Thromb Haemost 2011;105: 3-4.
51. Gurbel PA, Bliden KP. Durability of platelet inhibition by clopidogrel. Am J Cardiol 2003;91: 1123-1125. (Pubitemid 36514934)
52. Freynhofer MK, Brozovic I, Bruno V, Farhan S, Vogel B, Jakl G, Willheim M, Hubl W, Wojta J, Huber K. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events. Thromb Haemost 2011;106: 230-239.
53. Judge HM, Buckland RJ, Sugidachi A, Jakubowski JA, Storey RF. Relationship between degree of P2Y12 receptor blockade and inhibition of P2Y12-mediated platelet function. Thromb Haemost 2010;103: 1210-1217.
54. Schumacher WA, Bostwick JS, Ogletree ML, Stewart AB, Steinbacher TE, Hua J, Price LA, Wong PC, Rehfuss RP. Biomarker optimization to track the antithrombotic and hemostatic effects of clopidogrel in rats. J Pharmacol Exp Ther 2007;322: 369-377. (Pubitemid 46956346)
55. Bal Dit Sollier C, Berge N, Boval B, Dubar M, Drouet L. Differential sensitivity and kinetics of response of different ex vivo tests monitoring functional variability of platelet response to clopidogrel. Thromb Haemost 2010;104: 571-581.